Spreco, A.; Dahlström, Ö.; Jöud, A.; Nordvall, D.; Fagerström, C.; Blomqvist, E.; Gustafsson, F.; Hinkula, J.; Schön, T.; Timpka, T.
Effectiveness of the BNT162b2 mRNA Vaccine Compared with Hybrid Immunity in Populations Prioritized and Non-Prioritized for COVID-19 Vaccination in 2021–2022: A Naturalistic Case-Control Study in Sweden. Vaccines 2022, 10, 1273.
https://doi.org/10.3390/vaccines10081273
AMA Style
Spreco A, Dahlström Ö, Jöud A, Nordvall D, Fagerström C, Blomqvist E, Gustafsson F, Hinkula J, Schön T, Timpka T.
Effectiveness of the BNT162b2 mRNA Vaccine Compared with Hybrid Immunity in Populations Prioritized and Non-Prioritized for COVID-19 Vaccination in 2021–2022: A Naturalistic Case-Control Study in Sweden. Vaccines. 2022; 10(8):1273.
https://doi.org/10.3390/vaccines10081273
Chicago/Turabian Style
Spreco, Armin, Örjan Dahlström, Anna Jöud, Dennis Nordvall, Cecilia Fagerström, Eva Blomqvist, Fredrik Gustafsson, Jorma Hinkula, Thomas Schön, and Toomas Timpka.
2022. "Effectiveness of the BNT162b2 mRNA Vaccine Compared with Hybrid Immunity in Populations Prioritized and Non-Prioritized for COVID-19 Vaccination in 2021–2022: A Naturalistic Case-Control Study in Sweden" Vaccines 10, no. 8: 1273.
https://doi.org/10.3390/vaccines10081273
APA Style
Spreco, A., Dahlström, Ö., Jöud, A., Nordvall, D., Fagerström, C., Blomqvist, E., Gustafsson, F., Hinkula, J., Schön, T., & Timpka, T.
(2022). Effectiveness of the BNT162b2 mRNA Vaccine Compared with Hybrid Immunity in Populations Prioritized and Non-Prioritized for COVID-19 Vaccination in 2021–2022: A Naturalistic Case-Control Study in Sweden. Vaccines, 10(8), 1273.
https://doi.org/10.3390/vaccines10081273
